Observational Study to Assess Natural History in Cockayne Syndrome Patients

An Observational Study to Assess the Natural History Including Growth and Hearing in Patients With Cockayne Syndrome

Sponsors

Lead Sponsor: DNage B.V.

Source DNage B.V.
Brief Summary

This is an Observational Study of children under the age of 11 diagnosed with Cockayne Syndrome to assess the natural progression of Cockayne Syndrome disease, with special attention to hearing and physical changes in length or height, weight, head circumference, and arm span during standard treatment.

The primary analytical objective is to determine the rate of linear growth over a 6-month period in children < 2 years of age and over a 12-month period in children ≥ 2 years of age.

Overall Status Terminated
Start Date September 2009
Completion Date February 2011
Primary Completion Date February 2011
Study Type Observational
Primary Outcome
Measure Time Frame
The primary objective is to determine the rate of linear growth over a 6-month period in children < 2 years of age and over a 12-month period in children ≥ 2 years of age. 6 -12 months
Secondary Outcome
Measure Time Frame
Hearing Test Results tabulated and with the severity/deficits to be correlated with patient age, height velocity, and Pediatric Evaluation of Disabilities Inventory (PEDI)Score 6-12 months
Enrollment 40
Condition
Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

- Pediatric patients with a documented diagnosis of CS, as suggested by clinical features and possible confirmation by genetic consultation and analysis

- Age of participation:

- At least 12 months of age at the time of signing Informed Consent/Assent

- Female patient's age will not be greater than 10 years of age at the time of signing Informed Consent/Assent

- Male patient's age will not be greater than 11 years of age at the time of signing Informed Consent/Assent

Exclusion Criteria:

- Severe contractures or physical deformities that in the opinion of the investigator would prevent accurate measurement of height, length and ulna length

- Patients that have taken growth hormone or growth hormone related medications within 12 months prior to the date of Informed Consent/Assent

- Known history of inborn error of hyperprolinemia (Type I or Type II)

- Clinical features present at the time of initial screening that are associated with the terminal phases of the natural progression of CS suggesting safe travel and completion of the study and its assessments to be unlikely as judged by the Investigator, including any of the following:

- Continuous or intermittent dependence on supplemental oxygen at home during the prior six months

- Two or more hospitalizations for pneumonia during the prior 12 months;

- A documented net weight loss of at least 10%, which has not been recovered and which includes a significant net weight loss (beyond the estimated error of the measurement) over the most recent 6 months, despite intensive nutritional support including the use of gastrostomy tube feedings

- Presence of scoliosis with a Cobb's angle of 30º or greater

Gender: All

Minimum Age: 1 Year

Maximum Age: 11 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
E. G. Neilan, MD, PhD Principal Investigator Boston Children's Hospital
Location
Facility:
Harvard medical School, Children's Hospital Boston, Division of Genetics & Metabolism | Boston, Massachusetts, 02115, United States
New York University Medical Center | New York, New York, 10016, United States
Hopitaux Universitaires de Strasbourg, Service de Pédiatrie 1 | Strasbourg, Cedex, 67098, France
St. Mary's Hospital, Genetic Medicine, 6th Floor, Oxford Road | Manchester, M13 9 WL, United Kingdom
Location Countries

France

United Kingdom

United States

Verification Date

June 2011

Responsible Party

Name Title: Dr. E. Neilan, Principal Investigator

Organization: Children's Hospital Boston

Keywords
Has Expanded Access No
Condition Browse
Study Design Info

Observational Model: Cohort

Source: ClinicalTrials.gov